In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social interactions, participants receiving pemivibart experienced a 1.9% rate of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results